Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 7/20 | 0.42 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.42 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.42 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679625 | 1.00 | FABP3 (0.49) | FABP3FABP4LIPGCYP3A4CYP2C19 | |
| SCHEMBL4676732 | 0.89 | KCNQ2 (0.46) | FABP3FABP4LIPGCYP3A4CYP2C19 | |
| SCHEMBL4680091 | 0.89 | KCNQ2 (0.46) | FABP3FABP4LIPGCYP3A4CYP2C19 | |
| SCHEMBL13853666 | 0.78 | LIPG (0.60) | FABP3FABP4LIPGCYP3A4CYP2C19 | |
| SCHEMBL4676452 | 0.77 | ANPEP (0.52) | MAPTKMT2A | |
| SCHEMBL4678494 | 0.77 | ALDH1A1 (0.60) | MEN1KMT2A | |
| SCHEMBL4677405 | 0.77 | ALDH1A1 (0.60) | MEN1KMT2A | |
| SCHEMBL4676430 | 0.77 | ANPEP (0.52) | MAPTKMT2A | |
| SCHEMBL4680722 | 0.75 | LMNA (0.42) | MAPTL3MBTL1MEN1KMT2AGAA | |
| SCHEMBL4677631 | 0.75 | MEN1 (0.53) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | claimed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | claimed |
| EP-1975153-A2 | Protease inhibitors | Prozymex A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1975153-A2 | Protease inhibitors | Prozymex A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | disclosed |
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| WO-2004106289-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155803-A1 | Protease inhibitors | DPP7, DPP9, DPP3 | FABP3 1578/4885FABP4 3630/4885LIPG 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.